Vor Biopharma (VOR) Other financing activities (2021 - 2026)
Vor Biopharma (VOR) reported Other financing activities of $127000.0 for Q1 2026, down 76.95% year-over-year from $551000.0 in Q1 2025, and down 80.25% on a QoQ basis from $643000.0 in Q3 2025.
Vor Biopharma (VOR) has 3 years of Other financing activities data on file, last reported at $127000.0 in Q1 2026.
- Quarterly Other financing activities fell 76.95% year-over-year to $127000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (up 139.75% YoY) and the FY2021 annual result came in at $2.2 million, changed N/A from the prior year.
- Other financing activities fell to $127000.0 in Q1 2026 per VOR's latest filing, from $643000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $643000.0 in Q3 2025 and bottomed at $127000.0 in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Vor Biopharma | 628.83 Mn | 628.83 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 127,000.00 |
| Mar 31, 2026 | 127,000.00 |
| Sep 30, 2025 | 643,000.00 |
| Sep 30, 2025 | 643,000.00 |
| Mar 31, 2025 | 551,000.00 |
| Mar 31, 2025 | 551,000.00 |
| Jun 30, 2021 | 471,000.00 |
| Jun 30, 2021 | 471,000.00 |
| Mar 31, 2021 | 1.74 Mn |
| Mar 31, 2021 | 1.74 Mn |